BURLINGTON, Mass., April 24, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal second quarter 2025 earnings which ended on March 31, 2025, on Wednesday May 7, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 7, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay ...

BURLINGTON, Mass., March 24, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, highlighting the Company's ongoing commitment to advancing its strategy and actions aligned with key ESG priorities. The report includes ESG data for the Company's fiscal year ended September 30, 2024.The report offers a comprehensive look at the Company's ESG approach and showcases accomplishments in three main pillars: Environmental ...

BURLINGTON, Mass., March 10, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) announced that Lawrence Y. Lin, Executive Vice President and Chief Financial Officer, will participate in the Virtual KeyBanc Capital Markets Healthcare Forum on Wednesday, March 19, 2025, which includes a presentation beginning at 10:30 am ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event.About Az ...

Investors in Azenta, Inc. (AZTA) need to pay close attention to the stock based on moves in the options market lately. That is because the Dec. 19, 2025 $22.5 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mea ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: December 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to _________ Commission File Number 000-25434 AZENTA, INC. (Exact name of registrant as specified in its charter) Delaware 04 ...

Conference Call 1 Fiscal First Quarter 2025 Financial Results Februar y 5, 2025 1 © 2025 Azenta, Inc. • All rights reserved Safe Harbor Statement This presentation contains certain non-GAAP measures which are provided to assist in an understanding of the Azenta business and its operational performance. These measures should always be considered in conjunction with the appropriate GAAP measure. Reconciliations of all non-GAAP amounts to the relevant "Safe Harbor" Statement under the U.S. Private Securities L ...

Financial Data and Key Metrics Changes - First quarter revenue was $148 million, representing a 4% year-over-year growth on both reported and organic basis [44][45] - Non-GAAP EPS for the quarter was $0.08, with adjusted EBITDA margin at 9%, reflecting a 400 basis points expansion year-over-year [45][46] - Free cash flow was $22 million for the quarter, with $530 million in cash, cash equivalents, and marketable securities at quarter-end [46][54] Business Line Data and Key Metrics Changes - Sample Management Solutions (SMS) revenue was $81 million, up 3% year-over-year, driven by growth in Sample Repository Solutions and Core Products [49] - Multiomics segment delivered revenue of $66 million, with a growth of 6% year-over-year, supported by strong performance in Next Generation Sequencing (NGS) and Gene Synthesis [51][52] Market Data and Key Metrics Changes - In China, organic revenue growth was 7%, outperforming the market despite macro challenges [52] - NGS grew 11% year-over-year, indicating stabilization in pricing and volume growth [51][122] Company Strategy and Development Direction - The company is focused on portfolio optimization, operational excellence, and value-enhancing capital allocation [20][22] - The Value Creation Committee has been established to oversee strategic initiatives and capital allocation decisions [35][112] - The company aims to maintain a disciplined approach to capital allocation, prioritizing growth initiatives and operational improvements over share buybacks [111][112] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about gradual market recovery, reiterating full-year 2025 guidance of organic revenue growth between 3% to 5% and adjusted EBITDA margin expansion of 300 basis points [19][55] - The management highlighted the importance of continuous improvement and simplification in operations to drive long-term value creation [22][24] Other Important Information - The results of B Medical Systems are now treated as discontinued operations, and the sale process is underway [4][17] - The company is implementing a new business system and operating model to enhance operational efficiency and performance [23][24] Q&A Session Summary Question: Size and timing of the U.K. Biocentre BioArc opportunity - Management confirmed that the BioArc Ultra project was included in guidance and is expected to be operational early in 2026 [60][62] Question: Impact of Illumina being added to the unreliable entity list in China - Management indicated low risk to NGS business in China, as most operations are partnered with BGI, allowing for flexibility in platform usage [64][66] Question: Guidance for Multiomics and potential deceleration - Management acknowledged that guidance reflects a cautious outlook, with NGS experiencing strong growth but potential challenges in Sanger Sequencing [70][72] Question: Status of B Medical sale process - Management stated that the sale process is still in initial stages, with a focus on maximizing value [82][83] Question: Exposure to tariffs in China, Mexico, and Canada - Management assessed that the impact of tariffs is immaterial, with minimal risk from operations in Mexico and Canada [89][90] Question: Guidance for Sample Management Solutions - Management noted that timing issues affected SMS performance, but a robust pipeline and backlog are in place for future growth [92][93] Question: Gross margin sustainability and operating margin ramp - Management expressed confidence in gross margin trajectory, with expectations for continued improvement [98] Question: Academic and government exposure and NIH impact - Management confirmed that recent delays in government-funded projects are expected to resume once funding decisions are made [102][103] Question: Cell and gene therapy market performance - Management reported strong progress in the auto cryo business related to cell and gene therapy, with significant growth observed [106] Question: Share buyback program and M&A strategy - Management clarified that share buybacks are a lower priority compared to growth initiatives and M&A opportunities, with a focus on demonstrating operational credibility first [111][112][114]

Business Strategy - Azenta, Inc. is pursuing the sale of its B Medical Systems segment to simplify its portfolio and focus on core businesses, aiming to drive revenue growth and profitability[2] - The company aims to enhance shareholder value through strategic evaluations and operational improvements[2] Financial Performance - Total revenue for the twelve months ended September 30, 2023, was $551,950,000, with product revenue at $176,100,000 and service revenue at $375,850,000[9] - Revenue from continuing operations for the twelve months ended September 30, 2023, was $551,950,000[16] - The company reported a net loss of $164,170,000 for the twelve months ended September 30, 2024, which includes a loss from discontinued operations of $140,531,000[9] - GAAP net loss from continuing operations for the twelve months ended September 30, 2023, was $(7,660,000)[14] - The company reported a GAAP net loss of $(164,170,000) for the twelve months ended September 30, 2024[14] Adjusted Financial Metrics - Adjusted operating income from continuing operations was $4,181,000 for the twelve months ended September 30, 2024, after accounting for various adjustments[12] - Adjusted EBITDA for the twelve months ended September 30, 2023, was $22,235,000, with an adjusted EBITDA margin of 4%[16] - Adjusted EBITDA for the six months ended June 30, 2024, was $29,155,000, with an adjusted EBITDA margin of 10%[16] - The company’s adjusted earnings before interest, taxes, depreciation, and amortization for the twelve months ended September 30, 2024, was $46,889,000[16] Losses and Charges - Operating loss from continuing operations for the twelve months ended September 30, 2024, was $50,561,000[12] - The company has incurred restructuring charges of $6,766,000 for the twelve months ended September 30, 2024[12] - Restructuring charges amounted to $4,577,000 for the twelve months ended September 30, 2023[14] - The company incurred stock-based compensation expenses of $8,830,000 for the twelve months ended September 30, 2023[14] - The company reported a loss from discontinued operations of $(6,596,000) for the three months ended September 30, 2023[14] Assets and Cash Flow - Total current assets amount to $832,807,000, with cash and cash equivalents at $280,030,000 and accounts receivable at $156,273,000 as of September 30, 2024[7] - Cash and cash equivalents decreased from $280,030,000 to $151,162,000 in short-term marketable securities as of September 30, 2024[7] - Interest income, net for the twelve months ended September 30, 2023, was $(43,541,000)[14] Discontinued Operations - As of November 12, 2024, the B Medical Systems segment qualifies as a discontinued operation under U.S. GAAP[3]

Core Insights - Azenta, Inc. reported financial results for the first quarter ended December 31, 2024, showing a revenue increase of 4% year-over-year to $148 million, driven by growth in Sample Management Solutions and Multiomics services [1][7][33] - The company experienced an operating loss of $11 million, with a diluted EPS from continuing operations of ($0.21), compared to ($0.13) in the same quarter last year [7][24] - Management expressed confidence in the company's market positioning and ongoing transformation initiatives, highlighting strong free cash flow and positive demand trends [3][14] Financial Performance - Revenue from continuing operations was $148 million, up 4% year-over-year, with organic growth also at 4% [7][33] - Sample Management Solutions revenue was $81 million, a 3% increase year-over-year, while Multiomics revenue reached $66 million, up 6% year-over-year [7][33] - Adjusted EBITDA for continuing operations was $13 million, with an adjusted EBITDA margin of 9.0%, reflecting a 400 basis point improvement year-over-year [14][7] Earnings Summary - Total diluted EPS was ($0.29), slightly down from ($0.28) a year ago, with a non-GAAP diluted EPS of $0.08, unchanged from the previous year [7][14][24] - Operating expenses increased by 3% year-over-year to $80 million, primarily due to higher selling, general, and administrative expenses [7][14] - The company ended the quarter with cash, cash equivalents, and marketable securities totaling $530 million, including $27 million from discontinued operations [14][19] Guidance and Outlook - Azenta reiterated its revenue guidance for fiscal year 2025, expecting total organic revenue growth in the range of 3% to 5% relative to fiscal 2024 [14][19] - The company anticipates an adjusted EBITDA margin expansion of approximately 300 basis points compared to fiscal 2024 [14][19]

Core Insights - Azenta, Inc. has elected Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors during the Annual Meeting of Stockholders [1] - Mr. Doshi is recognized for his significant experience in the biotechnology and pharmaceutical industries, making him a valuable addition to the Board [2] - Mr. Doshi expressed enthusiasm about joining Azenta, highlighting the company's strong market leadership and commitment to growth and innovation [3] Company Overview - Azenta, Inc. is a leading provider of life sciences solutions, facilitating faster market access for breakthroughs and therapies [5] - The company offers a comprehensive suite of cold-chain sample management solutions and multiomics services, catering to drug development, clinical research, and advanced cell therapies [5] - Azenta operates globally with a presence in North America, Europe, and Asia, and is headquartered in Burlington, MA [6] Leadership Background - Dipal Doshi has extensive experience in the biotechnology and pharmaceutical sectors, having held critical roles in business development, corporate strategy, and finance [3] - Prior to his role at Entrada Therapeutics, Mr. Doshi served as Chief Business Officer at Amicus Therapeutics and has experience in investment banking with Merrill Lynch [4] - He holds an MBA from The Wharton School and a BA from Rutgers University, and is involved with other organizations in the life sciences sector [4]